Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

<p>Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care, including the potential for every two- or three-month dosing Initial subcutaneous pharmacokinetic and safety data from healthy volunteers anticipated in mid-2024 First product candidate to enter the clinic from the company’s strategic collaboration with Paragon Therapeutics, Inc., an innovative discovery […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/apogee-announces-first-participants-dosed-ahead-of-schedule-in-phase-1-trial-of-apg777-its-novel-half-life-extended-anti-il-13-antibody-for-the-treatment-of-atopic-dermatitis-and-other-inflammatory-d/">Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>